Patents by Inventor Simon Charles

Simon Charles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7279580
    Abstract: A class of 8-fluoro-3-phenylimidazo[1,2-?]pyridine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group, or by a pyrrolidinonyl group, which is directly attached or bridged by an oxygen atom or by a —NH— or —OCH2— linkage, being selective ligands for GABAA receptors, in particular having high affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: October 9, 2007
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Simon Charles Goodacre, David James Hallett, Alexander Charles Humphries, Philip Jones, Sarah Margaret Kelly, Kevin John Merchant, Kevin William Moore, Michael Reader
  • Patent number: 7231476
    Abstract: A processor operable to perform a plurality of functions, the processor comprising: an input port; a storage element operable to receive and to store an input signal input via the input port, the input signal comprising at least one control value; control logic operable to control at least one of the functions of the processor in dependence on the at least one control value; and access logic operable to receive an access control signal and to disable access via the input port to the at least one control value stored in the storage element in dependence upon the access control signal.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: June 12, 2007
    Assignee: ARM Limited
    Inventors: Simon Charles Watt, Luc Orion, Nicolas Chaussade
  • Patent number: 7226926
    Abstract: A class of 8-fluoroimidazo[1,2-?]pyridine derivatives, substituted at the 3-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having high affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: June 5, 2007
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Wesley Peter Blackaby, Jose Luis Castro Pineiro, Simon Charles Goodacre, David James Hallett, Alexander Charles Humphries, Philip Jones, Kevin John Merchant, Michael Reader
  • Patent number: 7185159
    Abstract: The present invention provides a data processing apparatus and method for accessing memory. The data processing apparatus has a secure domain and a non-secure domain, in the secure domain the data processing apparatus having access to secure data which is not accessible in the non-secure domain. The data processing apparatus comprises a device coupled via a device bus with the memory, the device being operable, when an item of data in the memory is required by the device, to issue onto the device bus a memory access request pertaining to either the secure domain or the non-secure domain. The memory is operable to store data required by the device, and contains secure memory for storing secure data and non-secure memory for storing non-secure data. In accordance with the invention, the memory access request as issued by the device includes a domain signal identifying whether the memory access request pertains to either the secure domain or the non-secure domain.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: February 27, 2007
    Assignee: Arm Limited
    Inventors: Lionel Beinet, David Hennah Mansell, Simon Charles Watt
  • Patent number: 7176203
    Abstract: A class of imidazo[1,2b][1,2,4]triazine derivatives, substituted at the 7-position by an optionally substituted five-membered or six-membered heteroaromatic ring, being selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: February 13, 2007
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Robert James Maxey, Michael Geoffrey Neil Russell, Leslie Joseph Street
  • Patent number: 7148222
    Abstract: The present invention discloses a compound of formula 1, or a pharmaceutically acceptable salt thereof: wherein X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Y represents a chemical bond, an oxygen atom, or a —NH— linkage; Z represents an optionally substituted aryl or heteroaryl group; R1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, —ORa, —SRa, —SORa, —SO2Ra, —SO2NRaRb, NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb or —CRa&?NORb; and Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group; a pharmaceutical composition comprising it; its use in a method of treatment; use of it to manufacture a medicament; and a method of using it to prevent or treat anxiety, convulsions or cognitive disorders.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: December 12, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Simon Charles Goodacre, David James Hallett
  • Patent number: 7149862
    Abstract: A data processing apparatus and method are provided for controlling access to a slave device, the slave device having an address range associated therewith. The apparatus comprises control storage programmable to define a partition identifying a secure region and a non-secure region in the address range, with the data processing apparatus supporting a plurality of modes of operation including a secure mode, and the control storage being programmable only by software executing in the secure mode. A master device is arranged to issue an access request onto a bus, the access request identifying a sequence of addresses within the address range and including a control signal indicating whether the access request is a secure access request or a non-secure access request. The secure region is only accessible by a secure access request.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: December 12, 2006
    Assignee: ARM Limited
    Inventors: Andrew David Tune, Peter James Aldworth, Simon Charles Watt, Lionel Belnet, David Hennah Mansell
  • Patent number: 7134003
    Abstract: A data processing system 2 is provided which is responsive to program instructions that operate in a variable timing mode to require a variable number of processing cycles to complete. The system is also operable in a fixed timing mode, which may be programmable using a bit (or several bits) within a configuration controlling register, to operate in a fixed timing mode in which such instructions are forced to operate using a fixed number of processing cycles. Thus, suppression of instructions which fail their condition codes may be suppressed and early termination of program instructions similarly suppressed in a manner which helps resist an attack upon the security of the system by observing the number of processing cycles required to process certain data.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: November 7, 2006
    Assignee: ARM Limited
    Inventor: Simon Charles Watt
  • Patent number: 7124274
    Abstract: An apparatus for processing data, the apparatus comprising: a processor operable in a plurality of modes and either a secure domain or a non-secure domain including at least one secure mode being a mode in the secure domain; and at least one non-secure mode being a mode in the non-secure domain. When the processor is executing a program in a secure mode, the program has access to secure data which is not accessible when the processor is operating in a non-secure mode. The processor further includes a non-secure translation table base address register and a secure translation table base address register operable in the non-secure and secure domain, respectively, to indicate a region of memory storing either non-secure or secure domain memory mapping data defining how virtual addresses are translated to physical addresses within either the non-secure or secure domain.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: October 17, 2006
    Assignee: Arm Limited
    Inventors: Simon Charles Watt, Christopher Bentley Dornan, Luc Orion, Nicolas Chaussade, Lionel Belnet, Stephane Eric Sebastien Brochier, David Hennah Mansell, Michael Robert Nonweiler
  • Patent number: 7117284
    Abstract: A data processing apparatus is operable in a plurality of modes and in either a secure domain or a non-secure domain. When operating in a secure mode within the secure domain a program has access to secure data which is not accessible when the processor is operating in a non-secure mode. A vectored interrupt controller is provided to generate an exception handler address in response to an occurrence of an except condition. The vectored interrupt controller is programmable with parameters specifying for each exception condition whether an exception handler in the secure or the non-secure domain should be triggered and an exception handler address for use if the exception occurs when in the appropriate domain. The vectored interrupt controller also includes a parameter specifying a domain switching exception handler address for use if the exception condition occurs when the processor is not in the appropriate domain.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: October 3, 2006
    Assignee: ARM Limited
    Inventors: Simon Charles Watt, Christopher Bentley Dornan, Luc Orion, Nicolas Chaussade, Lionel Belnet, Stephane Eric Sebastien Brochier, David Hennah Mansell, Jonathan Sean Callan
  • Patent number: 7045167
    Abstract: A device for the application of solid particulate material to a target surface includes one or more containers for storing the solid particulate material and one or more transfer devices for transferring the solid particulate material from the containers to the target surface. Each container includes one or more gates positioned substantially at the container's outlet. Mechanisms are provided for controlling the extent to which each individual gate opens, while the device is in use; and for controlling the rate at which the transfer devices transfer the solid particulate material from the containers while the device for the application of solid particulate material to a target surface is in use.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: May 16, 2006
    Assignee: J&K Development LLC
    Inventors: James Nelson Maytum, Simon Charles Peter Jennings, Philip Kearne
  • Patent number: 7030128
    Abstract: A class of imidazo[1,2-?]pyrimidine derivatives, substituted at the 3-position by an optionally substituted five-membered or six-membered heteroaromatic ring, are selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: April 18, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Wesley Peter Blackaby, Jose Luis Castro Pineiro, Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Philip Jones, Richard Thomas Lewis, Angus Murray MacLeod, Robert James Maxey, Kevin William Moore, Leslie Joseph Street
  • Patent number: 7005431
    Abstract: A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and substituted on the phenyl ring by one or two further substituents as defined herein, being selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: February 28, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Michela Bettati, Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Michael Geoffrey Neil Russell, Leslie Jospeh Street
  • Patent number: 7001018
    Abstract: A fixation apparatus is provided that limits rotation of the ocular globe of an eye, to facilitate alignment of an instrument with the axis of astigmatism of the eye. The apparatus includes fixation target means (12) for locating in the field of view of the eye so that the eye may fixate on the target. The fixation target means includes or consists of at least one elongate component (16). Also disclosed is a corresponding method, and method and apparatus for supplying visual feedback to an operator during refractive surgery of an eye of a patient.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: February 21, 2006
    Assignee: Q-Vis Limited
    Inventor: Simon Charles Martin
  • Patent number: 6969716
    Abstract: The present invention provides a compound of formula I, or an N-oxide thereof or a pharmaceutically acceptable salt thereof: wherein X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Z represents hydrogen, halogen, cyano, cyanomethyl, trifluoromethyl, nitro, hydroxy, hydroxy(C1-6)alkyl, C1-6 alkoxy, C1-6 alkoxy(C1-6)alkyl, trifluoromethoxy, trifluoromethylthio, trifluoromethanesulfinyl, formyl, C2-6 alkoxycarbonyl, oxopyrrolidinyl, or an optionally substituted aryl, heteroaryl or heteroaryl(C1-6)alkoxy group; and R1 represents aryl or heteroaryl, either of which groups may be optionally substituted; pharmaceutical compositions comprising it, its use in therapy and methods of treatment of anxiety and/or depression using it.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: November 29, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Wesley Peter Blackaby, Simon Charles Goodacre, David James Hallett, Andrew Jennings, Richard Thomas Lewis, Leslie Joseph Street, Kevin Wilson
  • Publication number: 20050257143
    Abstract: A display device is arranged to emulate a conventional computer printer, thereby allowing documents and/or images to be displayed in a simple and convenient manner, using conventional printer interconnection techniques and which allows the image or document to be displayed without inclusion of any elements of the graphical user interface provided by the software application that generated the image or document. The display device may also include storage medium for storing one or more images to be subsequently displayed on the display device 12.
    Type: Application
    Filed: May 14, 2003
    Publication date: November 17, 2005
    Applicant: THE APPLIANCE STUDIO LIMITED
    Inventor: Simon Charles Lewis
  • Patent number: 6914060
    Abstract: The present invention relates to imidazo[2,1-f]triazin-4-one analogues which are substituted in the 7-position by a substituted phenyl ring, being ligands for GABAA receptors and accordingly of benefit in the therapy of deleterious neurological disorders.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: July 5, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventor: Simon Charles Goodacre
  • Patent number: 6914063
    Abstract: A class of imidazo[1,2-?]pyrazine analogues substituted in the 3-position by a substituted phenyl ring, being selective ligands for GABAA receptors which interact more favourably with the ?2 and/or ?3 subunit than with the ?1 subunit, are accordingly of benefit in the treatment and/or prevention of a variety of disorders of the central nervous system, including anxiety and convulsions, with a reduced propensity to cause sedation.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: July 5, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Simon Charles Goodacre, David James Hallett, Leslie Joseph Street
  • Patent number: 6900215
    Abstract: A class of 3-phenylimidazo[1,2-?]pyrimidine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and further substituted on the phenyl ring by alkyl, trifluoromethyl, alkoxy or one or two halogen atoms, especially fluoro, are selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 31, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Simon Charles Goodacre, David James Hallett, Andrew Jennings, Philip Jones, Richard Thomas Lewis, Kevin William Moore, Michael Geoffrey Neil Russell, Leslie Joseph Street, Helen Jane Szekeres
  • Patent number: 6887885
    Abstract: A compound of formula I, or a pharmaceutically acceptable salt thereof: wherein X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Y represents a chemical bond, an oxygen atom, or a —NH— linkage; Z represents an optionally substituted aryl or heteroaryl group; R1 represents hydrocarbon, a heterocyclic group, trifluoromethyl, —SO2Ra, —SO2NRaRb, —CORa, —CO2Ra or —CONRaRb; and Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group; pharmaceutical compositions including the compound and methods for treating anxiety, convulsions and cognitive disorders are disclosed.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: May 3, 2005
    Assignee: Merck Sharp & Dohme Ltd
    Inventor: Simon Charles Goodacre